Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

(2020) Saad Z Usmani et al.   Lancet Haematology

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

(2019) Paul G Richardson et al.   LANCET ONCOLOGY

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)

(2018) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

(2018) Paul G Richardson et al.   Future Oncology

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016

(2018) Marc S. Raab et al.   BRITISH JOURNAL OF HAEMATOLOGY

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

(2018) Paul G. Richardson et al.   Blood Cancer Journal

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

(2016) Niels W. C. J. van de Donk et al.   IMMUNOLOGICAL REVIEWS

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Multiple Myeloma: Diagnosis and Treatment

(2016) S. Vincent Rajkumar et al.   MAYO CLINIC PROCEEDINGS

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapies targeting CD38 in Multiple Myeloma

(2016) Djordje Atanackovic et al.   OncoImmunology

Guidelines for determination of the number of prior lines of therapy in multiple myeloma

(2015) S. V. Rajkumar et al.   BLOOD

Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States

(2015) Xue Song et al.   CURRENT MEDICAL RESEARCH AND OPINION

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

(2015) J Laubach et al.   LEUKEMIA

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH